FOLD
Amicus Therapeutics, Inc. NASDAQ$14.49
Mkt Cap $4.5B
52w Low $5.51
99.9% of range
52w High $14.50
50d MA $14.40
200d MA $10.88
P/E (TTM)
-164.8x
EV/EBITDA
86.6x
P/B
16.3x
Debt/Equity
1.8x
ROE
-9.9%
P/FCF
147.1x
RSI (14)
—
ATR (14)
—
Beta
0.48
50d MA
$14.40
200d MA
$10.88
Avg Volume
4.2M
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | AMC | 0.07 | 0.01 | -86.0% | 14.34 | -0.1% | +0.1% | +0.1% | +0.0% | -0.1% | +0.2% | +0.6% | — |
| Nov 4, 2025 | AMC | 0.12 | 0.17 | +41.7% | 8.99 | +0.7% | +2.2% | -1.0% | -1.3% | +0.1% | +3.7% | +10.7% | — |
| Jul 31, 2025 | AMC | 0.02 | 0.01 | -50.0% | 5.99 | -0.5% | +5.5% | +14.0% | +16.7% | +15.7% | +13.4% | +31.6% | — |
| May 1, 2025 | AMC | 0.08 | 0.03 | -62.5% | 6.68 | +0.1% | -0.1% | -2.2% | -7.3% | -8.8% | -9.0% | -7.8% | — |
| Feb 19, 2025 | AMC | 0.02 | 0.09 | +350.0% | 9.56 | -1.5% | -5.1% | -3.9% | -2.3% | -4.7% | -5.5% | -5.8% | — |
| Nov 6, 2024 | AMC | 0.08 | 0.10 | +25.0% | 11.24 | +0.0% | -2.3% | -2.2% | -4.9% | -6.7% | -7.7% | -13.4% | — |
| Aug 8, 2024 | AMC | 0.05 | 0.06 | +9.9% | 11.32 | +0.6% | +1.4% | +2.3% | +3.5% | +1.6% | +1.1% | +1.7% | — |
| May 9, 2024 | AMC | -0.06 | -0.02 | +66.7% | 9.48 | +0.2% | -2.6% | -4.6% | -1.6% | +1.9% | +0.2% | +6.0% | — |
| Feb 28, 2024 | AMC | -0.06 | -0.11 | -83.3% | 12.95 | +1.5% | -1.0% | +2.6% | +3.9% | +3.1% | -2.7% | -9.3% | — |
| Nov 8, 2023 | AMC | -0.08 | -0.07 | +12.5% | 11.36 | +0.0% | -12.2% | -8.4% | -9.6% | -5.2% | -6.2% | -1.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 22 | Jefferies | Downgrade | Buy → Hold | — | $14.35 | $14.32 | -0.2% | -0.6% | -0.6% | -0.4% | -0.4% | -0.5% |
| Dec 29 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $14.25 | $14.24 | -0.1% | +0.0% | +0.0% | -0.1% | +0.1% | +0.0% |
| Dec 22 | Citigroup | Downgrade | Buy → Neutral | — | $14.18 | $14.19 | +0.1% | +0.2% | +0.2% | +0.5% | +0.5% | +0.5% |
| Dec 19 | Needham | Downgrade | Buy → Hold | — | $10.89 | $14.18 | +30.2% | +30.2% | +30.5% | +30.5% | +30.9% | +30.9% |
| Dec 19 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $10.89 | $14.18 | +30.2% | +30.2% | +30.5% | +30.5% | +30.9% | +30.9% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $9.19 | $9.20 | +0.1% | -3.2% | -3.5% | -2.1% | +1.4% | +2.5% |
| Nov 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $8.99 | $9.05 | +0.7% | +2.2% | -1.0% | -1.3% | +0.1% | +3.7% |
| Sep 18 | Needham | Upgrade | Hold → Buy | — | $7.97 | $8.48 | +6.4% | +6.4% | +4.5% | +7.5% | +2.4% | +4.8% |
| Jul 17 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $6.07 | $6.55 | +7.9% | +3.6% | -1.8% | -0.3% | +2.5% | +4.0% |
| May 2 | UBS | Maintains | Buy → Buy | — | $6.68 | $6.69 | +0.1% | -0.1% | -2.2% | -7.3% | -8.8% | -9.0% |
Recent Filings
8-K · 2.01
!!! Very High
BioMarin Pharmaceuticals Inc -- 8-K 2.01: Acquisition Completed
BioMarin Pharmaceuticals completed its acquisition of Folding@Home, expanding its portfolio and potentially enhancing drug discovery capabilities through distributed computing technology.
Apr 27
8-K · 5.02
!!! Very High
Amicus Therapeutics, Inc -- 8-K 5.02: Executive Change
Amicus Therapeutics was acquired in a deal where out-of-the-money employee stock options were cancelled without compensation, while in-the-money options received consideration.
Apr 27
8-K
BioMarin Pharmaceuticals Inc -- 8-K Filing
BioMarin Pharmaceuticals disclosed forward-looking statements regarding future events with material risks that could cause actual results to differ significantly from current expectations.
Apr 23
8-K
Amicus Therapeutics, Inc -- 8-K Filing
Amicus Therapeutics issued forward-looking statements regarding future events and expectations, indicating the company plans strategic initiatives subject to significant risks and uncertainties.
Apr 23
8-K
Amicus Therapeutics, Inc -- 8-K Filing
Amicus Therapeutics' shareholders approved a merger making the company a wholly owned subsidiary of Parent company, eliminating FOLD's independent status and providing liquidity for existing shareholders.
Mar 3
8-K
BioMarin Pharmaceuticals Inc -- 8-K Filing
I cannot provide a meaningful analysis as the summary provided does not contain substantive information about a specific transaction, announcement, or material event affecting BioMarin Pharmaceuticals.
Feb 23
8-K
Amicus Therapeutics, Inc -- 8-K Filing
Amicus Therapeutics reported 2025 revenue of $634M (up 17% YoY) with $294M cash, while its proposed acquisition by BioMarin remains on track to close in Q2 2026.
Feb 20
8-K · 1.01
! Medium
BioMarin Pharmaceuticals Inc -- 8-K 1.01: Financing / Debt Agreement
BioMarin completed an $850 million private placement of 5.500% senior notes due 2026, securing debt financing from qualified institutional buyers to fund operations and strategic initiatives.
Feb 12
Data updated apr 25, 2026 9:42am
· Source: massive.com